SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-17-006055
Filing Date
2017-08-07
Accepted
2017-08-07 08:07:16
Documents
60
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 6-K sbbp-20170630x6k.htm 6-K 1452435
  Complete submission text file 0001558370-17-006055.txt   5302005

Data Files

Seq Description Document Type Size
2 EX-101.INS sbbp-20170630.xml EX-101.INS 1031613
3 EX-101.SCH sbbp-20170630.xsd EX-101.SCH 43579
4 EX-101.CAL sbbp-20170630_cal.xml EX-101.CAL 47145
5 EX-101.DEF sbbp-20170630_def.xml EX-101.DEF 137549
6 EX-101.LAB sbbp-20170630_lab.xml EX-101.LAB 403361
7 EX-101.PRE sbbp-20170630_pre.xml EX-101.PRE 293661
Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Filer) CIK: 0001634432 (see all company filings)

IRS No.: 981130690 | State of Incorp.: L2
Type: 6-K | Act: 34 | File No.: 001-37569 | Film No.: 171010113
SIC: 2834 Pharmaceutical Preparations